Allison Ramsey, MD
Allergy · Rochester, NYNPI 1164534848
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $498,206 of the $643,219 with a category attached, or 77.5%. 20 manufacturers reported payments, led by Sanofi at 35.9% of the total. Among allergy clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 613 payments — averaging $1049.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$231K
- GSK$155K
- Regeneron Healthcare Solutions, Inc.$119K
- AstraZeneca$50K
- Novartis$34K
- CSL Behring$18K
- plus $37K from 14 others
Across 600 payments — averaging $458.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$204K
- Sanofi US Services Inc.$28K
- Astrazeneca UK Limited$18K
- GSK$15K
- Novartis$7K
- Sanofi$4K
What the payments were for
- Consulting fees$85,90813%
- Speaking & faculty fees$498,20677%
- Travel & lodging$37,6026%
- Food & beverage$21,4373%
- Education$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 172 | $230,892 |
| GSK | 130 | $154,944 |
| Regeneron Healthcare Solutions, Inc. | 103 | $118,879 |
| AstraZeneca | 66 | $49,561 |
| Novartis | 48 | $33,644 |
| CSL Behring | 20 | $18,293 |
| Regeneron | 18 | $14,763 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $6,458 |
| Covis Pharma GmbH | 3 | $5,279 |
| Pfizer | 9 | $3,886 |
| Pharming Healthcare, Inc. | 2 | $2,304 |
| Genentech USA, Inc. | 12 | $2,200 |
| Astrazeneca UK Limited | 1 | $1,074 |
| Grifols USA, LLC | 3 | $297 |
| Amgen | 3 | $163 |
| Alk-abello, Inc | 2 | $146 |
| Biocryst US Sales Co., LLC | 1 | $125 |
| Shire North American Group Inc | 2 | $122 |
| Optinose US, Inc. | 1 | $119 |
| Chiesi USA, Inc. | 3 | $71 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$643,219 in reported general payments places this provider in the 95th percentile of 92 allergy providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 28 | $125,726 |
| XolairOmalizumab | 32 | $106,840 |
| TezspireTezepelumab-Ekko | 14 | $85,499 |
| NucalaMepolizumab | 11 | $43,530 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $24,822 |
| SymbicortBudesonide/Formoterol Fumarate | 32 | $10,829 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $6,881 |
| Spiriva HandihalerTiotropium Bromide | 11 | $5,771 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $3,750 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $3,479 |
| Epinephrine | 13 | $2,607 |
| BreynaBudesonide/Formoterol Fumarate | 12 | $2,072 |
| Azelastine Hcl | 53 | $1,789 |
| Levocetirizine Dihydrochloride | 112 | $1,189 |
| Mometasone Furoate | 16 | $987 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Symbicort | $49,561 | $96,32846 claims |
| GSKNucala, Trelegy Ellipta, Breo Ellipta | $154,944 | $72,10157 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 92 allergy providers in New York.
Other allergy in Rochester
- Anitha ShrikhandeRochester$2K
- Marc BraunsteinHewlett$884K
- Christopher SmithHorseheads$622K
- Anne MaitlandTarrytown$292K
- Yudhistira PersaudBronx$127K
- Michael KatlanAlbany$91K
- Michel AklJamestown$90K
- Juan SotomayorNorth Syracuse$64K
- Alan KaufmanMount Vernon$60K
- Alissa McInerneyAstoria$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.